This Micro Cap Found Tremendous Mid-Week Success On Key Announcement

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, January 21, 2025

A Pennsylvania-based healthcare company turned heads on Tuesday following an announcement that the company exceeded its initial enrollment target for its stroke pivotal study, according to a press release this morning.

Traders wasted no time scooping up shares of Helius Medical Technologies Inc. (Nasdaq:HSDT) as the buying pressure pushed this micro cap up to $1.60/share (+113.05%) at the session high. This move could indicate a breakout from the trading range this stock has been corralled by since mid-summer 2024.

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. The company derives its revenue from Product Sales, fees and; license sources.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.